Loading clinical trials...
Loading clinical trials...
Phase 1 (Dose Escalation)/Phase 2 (Expansion Cohort) Trial of TY101 as a Single Agent in Patients With Locally Advanced/Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Conditions
Interventions
TY101
Locations
3
China
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Start Date
December 7, 2020
Primary Completion Date
June 30, 2024
Completion Date
July 31, 2025
Last Updated
August 13, 2021
Lead Sponsor
Tayu Huaxia Biotech Medical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions